<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353193</url>
  </required_header>
  <id_info>
    <org_study_id>INFUTER</org_study_id>
    <secondary_id>2019-004328-39</secondary_id>
    <nct_id>NCT04353193</nct_id>
  </id_info>
  <brief_title>Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.</brief_title>
  <acronym>INFUTER</acronym>
  <official_title>Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to compare the effects of terlipressin and octreotide in the reduction of
      portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with
      liver cirrhosis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HVPG</measure>
    <time_frame>30 minutes, 1 hour and 2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Liver Cirrhosis Portal</condition>
  <arm_group>
    <arm_group_label>Terlipressin IV bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terlipressin 1mg IV bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terlipressin IV continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide IV bolus plus continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin 1mg IV bolus</description>
    <arm_group_label>Terlipressin IV bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours</description>
    <arm_group_label>Terlipressin IV continuous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours</description>
    <arm_group_label>Octreotide IV bolus plus continuous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-75 years old.

          2. Liver Cirrhosis

          3. Portal hypertension

          4. Stable disease in the absence of vasoactive agents

          5. Signed informed consent form

        Exclusion Criteria:

          -  1. Patients on medications that can prolong QT interval 2. Patients with HCC not
             fulfilling Milan criteria for transplant 3. Grade II-IV hepatic encephalopathy 4. GI
             bleeding in the last 10 days 5. Child-Pugh C above 12 points 6. Bacterial infection in
             the last 10 days 7. HVPG &lt;12mmHg 8. Plasma sodium &lt;130mmol/l 9. Serum creatinine
             &gt;2mg/dl 10. Serum bilirubin &gt;5mg/dl 11. INR&gt;2.5 12. Uncontrolled cardiovascular
             disease 13. HIV infection 14. Extra hepatic malignancies 15. Heart failure NYHA Grade
             III/IV, COPD GOLD&gt;2 16. Morbid obesity 17. Coronary heart disease or intestinal
             ischemia 18. Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan Carlos Garcia-Pagan, MD</last_name>
    <phone>+34932275400</phone>
    <phone_ext>5790</phone_ext>
    <email>jcgarcia@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

